Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

cell therapy

This page shows the latest cell therapy news and features for those working in and with pharma, biotech and healthcare.

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

cell therapy candidates. ... DLBCL is the most common type of aggressive lymphoma, accounting for approximately one-third of B-cell lymphomas globally.

Latest news

More from news
Approximately 25 fully matching, plus 378 partially matching documents found.

Latest Intelligence

  • Gene therapy, gene editing and perspectives on future use in Parkinson’s disease Gene therapy, gene editing and perspectives on future use in Parkinson’s disease

    Vertex, who produce the therapy, has regulatory submissions underway in the USA and EU for sickle cell anaemia and β thalassaemia – the patient’s own cells are edited outside the body ... These three gene therapy approaches have been used in various

  • ASH 2022: bad blood but big advances ASH 2022: bad blood but big advances

    CAR-T is offering an improvement on invasive stem cell therapy, manipulating cells to hunt down and kill cancer cells. ... One of the most groundbreaking announcements came in mantle cell lymphoma (MCL), where – as with many haematologic malignancies

  • Meeting healthcare’s rising challenges Meeting healthcare’s rising challenges

    The promise is appealing, with a McKinsey report forecasting that healthcare innovations – from digital tools to gene and cell therapy – could reduce the total burden of disease in the world by

  • CAR-T cell therapy in oncology CAR-T cell therapy in oncology

    Next generation CAR-T cell therapy. First generation, autologous CAR-T cell immunotherapies have demonstrated significant clinical promise. ... However, it is well recognised that the full potential of CAR-T cell therapy has yet to be fully exploited.

  • Who needs to be trusted anyway? Who needs to be trusted anyway?

    see wholesale change in healthcare (ASGCT, Gene, Cell, &RNA Therapy Landscape Report). ... get one shot at a treatment that could offer the chance of a cure (Molecular Therapy, Immune Responses to Viral Gene Therapy Vectors).

More from intelligence
Approximately 1 fully matching, plus 57 partially matching documents found.

Latest appointments

  • Health comms agency emotive hires new cell and gene therapy leader Health comms agency emotive hires new cell and gene therapy leader

    Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where

  • Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

    Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology. ... Miguel Forte, chief executive officer of Zelluna, said:

More from appointments
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 24 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story
...
Working together to achieve better patient pathways
Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.
How design can lead improvement within Pharma...

Quick links